Is metastatic prostate cancer changing, and how will we know it? It's time for standard nomenclature for nonosseous metastases in clinical trials of patients with metastatic castration resistant prostate cancer.
Successful phenotype-genotype correlation is critically dependent on precise definition and reporting of end points in clinical trials. An uniform nomenclature for "deep phenotyping" of metastatic sites in patients with castration-resistant prostate cancer should be mandated in future clinical drug development.